试验设计：糖尿病患者被随机分成逐渐增加至每天8 mg的罗格列酮组（n=333）和逐渐增加至每天15 mg的格列吡嗪组（n=339）。在起始和18个月时行血管内超声检查。

结果
    ● 粥样斑块变化百分比：罗格列酮组-0.21%，格列吡嗪组0.43% （P=0.12）。
    ● 粥样斑块总体积变化：分别为-3.9  mm3和1.2  mm3（P=0.04）。
    ● 病死率：分别为2.4%和2.1%。
    ● 心肌梗死：分别为2.1%和1.8%。

结论
    ● 在2型糖尿病患者中，与应用格列吡嗪相比，罗格列酮没有减少粥样斑块变化的百分比。
    ● 应用罗格列酮后，粥样斑块总体积减少。
    ● 两组心血管事件结果相似（本研究样本量小，不足以显示预后终点差别，预后也不是本研究的主要终点）。
    ● 两组的心血管死亡率和心血管住院率（P=0.14），6分钟步行距离（P=0.26）相似，但运动训练组峰值氧耗量增加。
    ● 两组的严重不良反应相似。

结论 
    ● 优化治疗方案的基础上，给予收缩性慢性心力衰竭患者运动训练是安全和有效的。
    ● 更加支持目前指南关于慢性心力衰竭患者运动建议的证据。

APPROACH试验摘要（研究设计及患者基线特征）：

BACKGROUND: Rosiglitazone， a thiazolidinedione， has effects on insulin sensitivity and cardiovascular risk factors that may favorably impact the progression of coronary atherosclerosis.

METHODS: APPROACH is a double-blind randomized clinical trial comparing the effects of the insulin sensitizer rosiglitazone with the insulin secretagogue glipizide on the progression of coronary atherosclerosis. Patients with type 2 diabetes and coronary artery disease undergoing clinically indicated coronary angiography or percutaneous coronary intervention are randomized to receive rosiglitazone or glipizide for 18 months using a titration algorithm designed to provide comparable glycemic control between treatment groups. The primary end point is change in percent atheroma volume from baseline to study completion in a nonintervened coronary artery， as measured by intravascular ultrasound. Cardiovascular events are adjudicated by an end point committee.

RESULTS: A total of 672 patients were randomized. The mean age was 61 years， hemoglobin A(1c) (HbA(1c)) 7.2%， body mass index 29.5 kg/m(2)， and median duration of diabetes 4.8 years. At baseline， approximately half of the participants were receiving oral antidiabetic monotherapy (53.9%) with 27.5% receiving dual combination therapy and 17.9% treated with diet and exercise alone. Approximately two thirds of the participants (68%) had dyslipidemia， 79.9% hypertension， and 24% prior myocardial infarction.

CONCLUSIONS: APPROACH has fully enrolled a high-risk patient population and will compare the glucose-independent effects of rosiglitazone and glipizide on the progression of coronary atherosclerosis， as well as provide additional data on the cardiovascular safety of rosiglitazone in patients with type 2 diabetes and coronary artery disease.